BSE Live
Mar 16, 14:30Prev. Close
4614.50
Open Price
4590.35
Bid Price (Qty.)
4685.35 (2)
Offer Price (Qty.)
4695.50 (3)
NSE Live
Mar 16, 14:30Prev. Close
4623.00
Open Price
4600.00
Bid Price (Qty.)
4691.50 (1)
Offer Price (Qty.)
4693.50 (5)
| Cash Flow of Pfizer (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 1,016.09 | 746.07 | 824.01 | 772.89 | 668.72 | |
| Net CashFlow From Operating Activities | 659.75 | 256.84 | 355.68 | 667.08 | 427.33 | |
| Net Cash Used In Investing Activities | -71.34 | 53.70 | -36.05 | -575.02 | -468.84 | |
| Net Cash Used From Financing Activities | -205.34 | -235.14 | -345.79 | -180.51 | -1,571.07 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 383.07 | 75.40 | -26.16 | -88.45 | -1,612.58 | |
| Cash And Cash Equivalents Begin of Year | 112.00 | 36.60 | 62.76 | 151.21 | 1,763.79 | |
| Cash And Cash Equivalents End Of Year | 495.07 | 112.00 | 36.60 | 62.76 | 151.21 |
10.02.2026
Pfizer Standalone December 2025 Net Sales at Rs 645.03 crore, up 19.9% Y-o-Y
13.11.2025
Pfizer Standalone September 2025 Net Sales at Rs 642.34 crore, up 9.13% Y-o-Y
20.05.2025
Pfizer Standalone March 2025 Net Sales at Rs 591.91 crore, up 8.28% Y-o-Y
01.02.2025
Pfizer Standalone December 2024 Net Sales at Rs 537.99 crore, down 0.37% Y-o-Y
19.10.2016
05.08.2016
03.01.2014
10.01.2011
16.03.2026
15.03.2026
13.03.2026
13.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth